Syncom Formulations Q3 FY26: ₹115 Cr Sales, ₹19 Cr Profit, 47% Profit Jump… But Why Is Stock Still Acting Like It Failed UPSC?
1. At a Glance – The Pharma Kid Who Studied Hard But Still Got Ignored
Syncom Formulations is that student in your class who quietly scored 90%, improved every year, didn’t cheat, didn’t create drama… and yet nobody invited him to the cool kids’ party.
We are talking about a ₹1,055 crore pharma company doing ₹501 crore sales, ₹69 crore profit, growing profits at 80% YoY, sitting almost debt-free, expanding injectables capacity, and even buying Mumbai real estate like a Gujarati uncle after a good Diwali bonus.
And yet?
Stock is down ~40% in one year.
Why?
Because the market is like Indian parents — “Beta Sharma ji ka ladka (Sun Pharma) dekh… ₹4 lakh crore market cap… tu kya kar raha hai?”
So here we are.
A smallcap pharma company:
With improving margins (OPM now 18%)
Strong domestic + export mix
Expanding into nutraceuticals + real estate (because why not?)
Zero debt almost (₹0.30 Cr — basically chai money)
But also:
Governance hiccups
Random penalties
CFO resignations
And a business model that feels like it has ADHD
So the big question is:
👉 Is this a hidden compounder… or a confused multi-business khichdi?
Let’s investigate like CID but with Excel sheets.
2. Introduction – Pharma Company or Multi-Level Side Hustle?
Syncom started in 1995 — classic Indian pharma story.
Generic medicines Export markets Low-cost manufacturing And dreams of becoming the next big thing
Fast forward to today:
500+ products
Presence in 25 countries
Mix of tablets, injectables, syrups, ointments
Sounds solid, right?
But then plot twist:
Trading commodities
Renting properties
Buying ₹51 Cr real estate in Mumbai
Adding nutraceuticals + power business in MOA
At this point, even the company’s CA must be like:
“Sir… main pharma ka accounts banaun ya real estate ka?”
3. Business Model – WTF Do They Even Do?
Let’s simplify this buffet:
Core Business (88%)
Pharmaceutical formulations:
Tablets (48%)
Injectables (17%)
Capsules, liquids, ointments
This is the real engine.
Side Hustles (12%)
Commodity trading (11%)
Rental income (1%)
Basically: Pharma company with “extra income for safety”.
Geography Split
International: 35%
Domestic: 35% (Rest unclear mix — but roughly balanced)
Brands & Divisions
CRATUS (domestic)
Syncom (international)
Now here’s the problem:
👉 Why is a small pharma company diversifying into:
Real estate
Nutraceuticals
Power sector
Is this ambition… or distraction?
Tell me honestly — would you trust a doctor who also runs a gym, a restaurant, and a real estate brokerage?
4. Financials Overview – Numbers Don’t Lie (But They Do Raise Eyebrows)
